Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells

Siti Norhaiza Hadzir, Siti Norsaidah Ibrahim, Rohaya Megat Abdul Wahab, Intan Zarina Zainol Abidin, Sahidan Senafi, Zaidah Zainal Ariffin, Mohamad ABDUL RAZAK, Shahrul Hisham Zainal Ariffin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background aims: Suspension mononuclear cells (MNCs) can be differentiated into osteoblasts with the induction of ascorbic acid and β-glycerophosphate. The aim of this study was to determine the ability of suspension MNCs to differentiate into osteoblasts using ascorbic acid only. Methods: Suspension MNCs were obtained by a combination of gradient centrifugation and culture selection. Suspension MNCs were subjected to differentiation assay by culturing them inside proliferation medium supplemented with 10 μg/mL, 30 μg/mL, 50 μg/mL, 60 μg/mL, 90 μg/mL and 500 μg/mL of ascorbic acid. Proliferation medium supplemented with 50 μg/mL ascorbic acid and 10mmol/L β-glycerophosphate was used as a positive control for osteoblast induction, and proliferation medium without ascorbic acid was used as a negative control. Differentiation analysis was performed using alkaline phosphatase (ALP) assay, von Kossa staining and expression of osteoblast-related genes. Results: With all concentrations of ascorbic acid used, there was a significant increase (P< 0.05) in ALP-specific activity and mineralized nodule formation throughout the differentiation course compared with negative control. Ascorbic acid was also able to activate the expression of osteopontin (SPP1), osteonectin (SPARC) and runt-related transcription factor 2 (RUNX2) messenger RNA in positive control and ascorbic acid-induced MNCs (30 μg/mL and 90μg/mL) but not in negative control. Conclusions: Ascorbic acid alone was sufficient to induce osteoblast differentiation from suspension MNCs; 30-90 μg/mL of ascorbic acid was found to be the optimal concentration. Ascorbic acid can be used as a nutritional supplement for cellular therapy of bone-related disease.

Original languageEnglish
Pages (from-to)674-682
Number of pages9
JournalCytotherapy
Volume16
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Osteoblasts
Ascorbic Acid
Suspensions
Glycerophosphates
Alkaline Phosphatase
Osteonectin
Osteopontin
Bone Diseases
Centrifugation
Transcription Factors
Staining and Labeling
Messenger RNA

Keywords

  • Alkaline phosphatase
  • Ascorbic acid
  • Mineralization
  • Osteoblasts
  • Suspension mononuclear cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Genetics(clinical)
  • Transplantation
  • Cancer Research
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells. / Hadzir, Siti Norhaiza; Ibrahim, Siti Norsaidah; Megat Abdul Wahab, Rohaya; Zainol Abidin, Intan Zarina; Senafi, Sahidan; Ariffin, Zaidah Zainal; ABDUL RAZAK, Mohamad; Zainal Ariffin, Shahrul Hisham.

In: Cytotherapy, Vol. 16, No. 5, 2014, p. 674-682.

Research output: Contribution to journalArticle

Hadzir, SN, Ibrahim, SN, Megat Abdul Wahab, R, Zainol Abidin, IZ, Senafi, S, Ariffin, ZZ, ABDUL RAZAK, M & Zainal Ariffin, SH 2014, 'Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells', Cytotherapy, vol. 16, no. 5, pp. 674-682. https://doi.org/10.1016/j.jcyt.2013.07.013
Hadzir, Siti Norhaiza ; Ibrahim, Siti Norsaidah ; Megat Abdul Wahab, Rohaya ; Zainol Abidin, Intan Zarina ; Senafi, Sahidan ; Ariffin, Zaidah Zainal ; ABDUL RAZAK, Mohamad ; Zainal Ariffin, Shahrul Hisham. / Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells. In: Cytotherapy. 2014 ; Vol. 16, No. 5. pp. 674-682.
@article{df1f181f2cf24283823cc1e2ffdab71f,
title = "Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells",
abstract = "Background aims: Suspension mononuclear cells (MNCs) can be differentiated into osteoblasts with the induction of ascorbic acid and β-glycerophosphate. The aim of this study was to determine the ability of suspension MNCs to differentiate into osteoblasts using ascorbic acid only. Methods: Suspension MNCs were obtained by a combination of gradient centrifugation and culture selection. Suspension MNCs were subjected to differentiation assay by culturing them inside proliferation medium supplemented with 10 μg/mL, 30 μg/mL, 50 μg/mL, 60 μg/mL, 90 μg/mL and 500 μg/mL of ascorbic acid. Proliferation medium supplemented with 50 μg/mL ascorbic acid and 10mmol/L β-glycerophosphate was used as a positive control for osteoblast induction, and proliferation medium without ascorbic acid was used as a negative control. Differentiation analysis was performed using alkaline phosphatase (ALP) assay, von Kossa staining and expression of osteoblast-related genes. Results: With all concentrations of ascorbic acid used, there was a significant increase (P< 0.05) in ALP-specific activity and mineralized nodule formation throughout the differentiation course compared with negative control. Ascorbic acid was also able to activate the expression of osteopontin (SPP1), osteonectin (SPARC) and runt-related transcription factor 2 (RUNX2) messenger RNA in positive control and ascorbic acid-induced MNCs (30 μg/mL and 90μg/mL) but not in negative control. Conclusions: Ascorbic acid alone was sufficient to induce osteoblast differentiation from suspension MNCs; 30-90 μg/mL of ascorbic acid was found to be the optimal concentration. Ascorbic acid can be used as a nutritional supplement for cellular therapy of bone-related disease.",
keywords = "Alkaline phosphatase, Ascorbic acid, Mineralization, Osteoblasts, Suspension mononuclear cell",
author = "Hadzir, {Siti Norhaiza} and Ibrahim, {Siti Norsaidah} and {Megat Abdul Wahab}, Rohaya and {Zainol Abidin}, {Intan Zarina} and Sahidan Senafi and Ariffin, {Zaidah Zainal} and {ABDUL RAZAK}, Mohamad and {Zainal Ariffin}, {Shahrul Hisham}",
year = "2014",
doi = "10.1016/j.jcyt.2013.07.013",
language = "English",
volume = "16",
pages = "674--682",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells

AU - Hadzir, Siti Norhaiza

AU - Ibrahim, Siti Norsaidah

AU - Megat Abdul Wahab, Rohaya

AU - Zainol Abidin, Intan Zarina

AU - Senafi, Sahidan

AU - Ariffin, Zaidah Zainal

AU - ABDUL RAZAK, Mohamad

AU - Zainal Ariffin, Shahrul Hisham

PY - 2014

Y1 - 2014

N2 - Background aims: Suspension mononuclear cells (MNCs) can be differentiated into osteoblasts with the induction of ascorbic acid and β-glycerophosphate. The aim of this study was to determine the ability of suspension MNCs to differentiate into osteoblasts using ascorbic acid only. Methods: Suspension MNCs were obtained by a combination of gradient centrifugation and culture selection. Suspension MNCs were subjected to differentiation assay by culturing them inside proliferation medium supplemented with 10 μg/mL, 30 μg/mL, 50 μg/mL, 60 μg/mL, 90 μg/mL and 500 μg/mL of ascorbic acid. Proliferation medium supplemented with 50 μg/mL ascorbic acid and 10mmol/L β-glycerophosphate was used as a positive control for osteoblast induction, and proliferation medium without ascorbic acid was used as a negative control. Differentiation analysis was performed using alkaline phosphatase (ALP) assay, von Kossa staining and expression of osteoblast-related genes. Results: With all concentrations of ascorbic acid used, there was a significant increase (P< 0.05) in ALP-specific activity and mineralized nodule formation throughout the differentiation course compared with negative control. Ascorbic acid was also able to activate the expression of osteopontin (SPP1), osteonectin (SPARC) and runt-related transcription factor 2 (RUNX2) messenger RNA in positive control and ascorbic acid-induced MNCs (30 μg/mL and 90μg/mL) but not in negative control. Conclusions: Ascorbic acid alone was sufficient to induce osteoblast differentiation from suspension MNCs; 30-90 μg/mL of ascorbic acid was found to be the optimal concentration. Ascorbic acid can be used as a nutritional supplement for cellular therapy of bone-related disease.

AB - Background aims: Suspension mononuclear cells (MNCs) can be differentiated into osteoblasts with the induction of ascorbic acid and β-glycerophosphate. The aim of this study was to determine the ability of suspension MNCs to differentiate into osteoblasts using ascorbic acid only. Methods: Suspension MNCs were obtained by a combination of gradient centrifugation and culture selection. Suspension MNCs were subjected to differentiation assay by culturing them inside proliferation medium supplemented with 10 μg/mL, 30 μg/mL, 50 μg/mL, 60 μg/mL, 90 μg/mL and 500 μg/mL of ascorbic acid. Proliferation medium supplemented with 50 μg/mL ascorbic acid and 10mmol/L β-glycerophosphate was used as a positive control for osteoblast induction, and proliferation medium without ascorbic acid was used as a negative control. Differentiation analysis was performed using alkaline phosphatase (ALP) assay, von Kossa staining and expression of osteoblast-related genes. Results: With all concentrations of ascorbic acid used, there was a significant increase (P< 0.05) in ALP-specific activity and mineralized nodule formation throughout the differentiation course compared with negative control. Ascorbic acid was also able to activate the expression of osteopontin (SPP1), osteonectin (SPARC) and runt-related transcription factor 2 (RUNX2) messenger RNA in positive control and ascorbic acid-induced MNCs (30 μg/mL and 90μg/mL) but not in negative control. Conclusions: Ascorbic acid alone was sufficient to induce osteoblast differentiation from suspension MNCs; 30-90 μg/mL of ascorbic acid was found to be the optimal concentration. Ascorbic acid can be used as a nutritional supplement for cellular therapy of bone-related disease.

KW - Alkaline phosphatase

KW - Ascorbic acid

KW - Mineralization

KW - Osteoblasts

KW - Suspension mononuclear cell

UR - http://www.scopus.com/inward/record.url?scp=84897966019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897966019&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.07.013

DO - 10.1016/j.jcyt.2013.07.013

M3 - Article

C2 - 24176546

AN - SCOPUS:84897966019

VL - 16

SP - 674

EP - 682

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 5

ER -